One possible explanation for the limited efficacy in NSCLC patients with liver metastasis treated with PD-1/PD-L1 inhibitors is the immune microenvironment, which is specific to liver metastasis as mentioned above, and the suppression of systemic immunity by liver metastasis. Here, PDCD1 is linked to non-small cell lung carcinoma.